EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Impact of Disease‐Specific Treatment and Non‐Selective Beta Blockers on Risk of PVT in Cirrhotic Patients With HCV or PBC

Humberto C Gonzalez iD, Stuart C Gordon iD, Sheri Trudeau, Trueman Wu, Lora Rupp, Christina Melkonian, Mark A Schmidt, Yihe G Daida, Amandeep K Sahota, Christopher L Bowlus, Mei Lu

Liver International · 2026-05 · 46 (5)

DOI: 10.1111/liv.70628 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, online erschienen am 03.04.2026. Verfasst von Humberto C Gonzalez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Henry Ford Health, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Liver Cirrhosis, Biliary, Adrenergic beta-Antagonists, Hepatitis C, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Portal vein thrombosis (PVT) is a common sequela of cirrhosis. Despite regression of fibrosis/cirrhosis observed among some patients after disease‐specific treatment, few studies have considered the role of treatment and response on risk of PVT among patients with cirrhosis across different liver disease states. We considered aetiological treatment and response as well as whether non‐selective beta‐blockers (NSBBs), statins, and anticoagulants were associated with risk of PVT.

Methods

We used data for patients with cirrhosis (compensated or decompensated) from two large, US‐based multisite cohort studies. Patients with hepatitis C (HCV) were drawn from the Chronic Hepatitis Cohort Study. Patients with primary biliary cholangitis (PBC) were drawn from the Fibrotic Liver Disease Consortium. Risk for PVT was assessed using a discrete survival model that includes both fixed covariates and time‐dependent variables.

Results

Among 6659 HCV patients, 274 developed PVT across ~13 years of follow‐up. Significant risk factors included time‐varying decompensated cirrhosis (adjusted hazard ratio [aHR] 27.41, 95% confidence interval [CI] 15.89–47.30), male sex (aHR 1.48, 95% CI 1.12–1.94), and use of NSBBs (aHR 2.07, 95% CI 1.61–2.67). Among 786 PBC patients, 67 developed PVT across ~8 years of follow‐up. Use of NSBBs was the only significant PVT risk factor in these patients (aHR 2.56, 95% CI 1.52–4.31). Neither sustained virological response [SVR] after antiviral treatment (HCV patients) nor response to ursodeoxycholic acid [UDCA] treatment (PBC patients) was associated with risk of PVT.

Conclusions

In two large well‐characterized samples of cirrhotic patients with HCV or PBC, disease‐specific treatments were not associated with PVT risk. NSBB treatment was independently associated with > 2 times the risk of PVT in both samples, regardless of compensated or decompensated status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisLiver Cirrhosis, BiliaryAdrenergic beta-AntagonistsHepatitis C, ChronicVenous ThrombosisPortal VeinHumansMaleFemaleRisk FactorsMiddle AgedAntiviral AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsAgedUnited StatesProportional Hazards ModelsUrsodeoxycholic AcidAdult

Stichwörter der Autor:innen

AASLDdecompensated cirrhosisstatinssustained virological response (SVR)ursodeoxycholic acid (UDCA)

Substanzen

Adrenergic beta-AntagonistsAntiviral AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsUrsodeoxycholic Acid

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Henry Ford Health, Detroit, Michigan, USA.
  • School of Medicine, Wayne State University, Detroit, Michigan, USA.
  • College of Human Medicine, Michigan State University, East Lansing, Michigan, USA.
  • Center for Health Policy and Health Services Research, Henry Ford Health, Detroit, Michigan, USA.
  • Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan, USA.
  • Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA.

ORCID-Profile: Humberto C Gonzalez, Stuart C Gordon

Zitieren

APA

Gonzalez, H. C., Gordon, S. C., Trudeau, S., Wu, T., Rupp, L., Melkonian, C., Schmidt, M. A., Daida, Y. G., Sahota, A. K., Bowlus, C. L., & Lu, M. (2026). Impact of Disease‐Specific Treatment and Non‐Selective Beta Blockers on Risk of PVT in Cirrhotic Patients With HCV or PBC. Liver International, 46(5). https://doi.org/10.1111/liv.70628

Vancouver

Gonzalez HC, Gordon SC, Trudeau S, Wu T, Rupp L, Melkonian C, et al. Impact of Disease‐Specific Treatment and Non‐Selective Beta Blockers on Risk of PVT in Cirrhotic Patients With HCV or PBC. Liver International. 2026;46(5). doi:10.1111/liv.70628

BibTeX
@article{Gonzalez2026,
  author = {Gonzalez, Humberto C and Gordon, Stuart C and Trudeau, Sheri and Wu, Trueman and Rupp, Lora and Melkonian, Christina and Schmidt, Mark A and Daida, Yihe G and Sahota, Amandeep K and Bowlus, Christopher L and Lu, Mei},
  title = {Impact of Disease‐Specific Treatment and Non‐Selective Beta Blockers on Risk of PVT in Cirrhotic Patients With HCV or PBC},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {5},
  doi = {10.1111/liv.70628}
}
Kostenlos starten →